Literature DB >> 24045970

Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS.

Abigail L Stockham1, Manmeet Ahluwalia, Chandana A Reddy, John H Suh, Aryavarta Kumar, Michael A Vogelbaum, Gene H Barnett, Erin S Murphy, Samuel T Chao.   

Abstract

Although stereotactic radiosurgery (SRS) is an effective treatment option for patients with brain tumors, its increased use has raised concern for increased incidence of radiation necrosis (RN). No established standard or guidelines exists regarding non-invasive techniques to diagnose or treat RN. This study was conducted to assess current patterns of evaluation and treatment of RN among physicians who treat intracranial malignancies. A questionnaire consisting of 20 questions was sent to 3,041 members of the American Society for Radiation Oncology (ASTRO) and the Society for Neurologic Oncology (SNO). Questions addressed demographics, utilization of SRS, perceptions regarding RN diagnosis treatment, approach to steroid-refractory RN, and management of two clinical scenarios using Kwiksurvey© software. The survey response rate was 8.74 % (266/3,041). Most respondents practice in an academic and/or university setting (62 %) at a facility that performs SRS (94 %) with a variety of systems. The number of annual cases performed at the participant's institution varied from <50 to >400, with a wide degree of variability. Most respondents practice at an institution that performs 50-100 cases/year (28 %). The most common range of symptomatic RN seen in clinical practice was 1-5 % (61 %). Most respondents reported that asymptomatic RN occurs in 6-10 % (33 %). Favored non-invasive diagnostic mechanisms were clinical evaluation (37 %) and MRI (19 %). In response to a clinical scenario depicting an asymptomatic patient post-SRS for brain metastasis with an enlarging lesion and edema at the treatment site, most respondents felt the image represented RN or a combination of RN and tumor progression. Most (58 %) favored short-term follow-up with repeat MRI. Ninety-three percent of the respondents initiated steroids as a first-line approach if patient was to develop symptoms. Steroids were the preferred first therapy in symptomatic patients on initial follow-up (81 %). In steroid-refractory patients, most recommend surgical intervention (63 %). Most physicians who responded to this questionnaire believe that post-SRS RN is uncommon (≤10 % of cases). The approach to establish the diagnosis of RN is variable. Steroids are the most commonly utilized first-line treatment for suspected RN. Considerable variation exists in the management of steroid-refractory RN. Additional studies are required to establish guidelines for evaluation and treatment of RN.

Entities:  

Mesh:

Year:  2013        PMID: 24045970     DOI: 10.1007/s11060-013-1248-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  The role of 99mTc-tetrofosmin brain SPECT in differentiating treatment-induced necrosis from recurrent brain tumor.

Authors:  George A Alexiou; Andreas D Fotopoulos; Spyridon Tsiouris; Spyridon Voulgaris; Athanasios P Kyritsis
Journal:  J Neurooncol       Date:  2010-12-28       Impact factor: 4.130

2.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

3.  Treatment of steroid refractory, Gamma Knife related radiation necrosis with bevacizumab: case report and review of the literature.

Authors:  Matthew R Sanborn; Shabbar F Danish; Myrna R Rosenfeld; Donald O'Rourke; John Y K Lee
Journal:  Clin Neurol Neurosurg       Date:  2011-09-08       Impact factor: 1.876

4.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

5.  The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy.

Authors:  Shaheenah Dawood; Asim Jamal Shaikh; Thomas A Buchholz; Javier Cortes; Massimo Cristofanilli; Sudeep Gupta; Ana M Gonzalez-Angulo
Journal:  Cancer       Date:  2011-10-05       Impact factor: 6.860

6.  Diagnosis and treatment of progressive space-occupying radiation necrosis following stereotactic radiosurgery for brain metastasis: value of proton magnetic resonance spectroscopy.

Authors:  T Kimura; K Sako; Y Tohyama; S Aizawa; H Yoshida; T Aburano; K Tanaka; T Tanaka
Journal:  Acta Neurochir (Wien)       Date:  2003-07       Impact factor: 2.216

7.  Induction of acute phase gene expression by brain irradiation.

Authors:  J H Hong; C S Chiang; I L Campbell; J R Sun; H R Withers; W H McBride
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-10-15       Impact factor: 7.038

8.  Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery.

Authors:  Brian J Blonigen; Ryan D Steinmetz; Linda Levin; Michael A Lamba; Ronald E Warnick; John C Breneman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

Review 9.  Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey.

Authors:  Y Martins; R I Lederman; C L Lowenstein; S Joffe; B A Neville; B T Hastings; G A Abel
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

10.  Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis.

Authors:  Giuseppe Minniti; Enrico Clarke; Gaetano Lanzetta; Mattia Falchetto Osti; Guido Trasimeni; Alessandro Bozzao; Andrea Romano; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2011-05-15       Impact factor: 3.481

View more
  13 in total

Review 1.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

2.  Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey.

Authors:  Tobias Walbert; Michael Glantz; Lonni Schultz; Vinay K Puduvalli
Journal:  J Neurooncol       Date:  2015-10-30       Impact factor: 4.130

3.  Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery.

Authors:  Mudit Chowdhary; Derick Okwan-Duodu; Jeffrey M Switchenko; Robert H Press; Jaymin Jhaveri; Zachary S Buchwald; Jim Zhong; Bhavana V Chapman; Ranjit S Bindra; Joseph N Contessa; Henry S Park; James B Yu; Roy H Decker; Jeffrey J Olson; Nelson M Oyesiku; Ross A Abrams; Hui-Kuo G Shu; Walter J Curran; Ian R Crocker; Kirtesh R Patel
Journal:  J Neurooncol       Date:  2017-11-09       Impact factor: 4.130

4.  International patterns of palliative care in neuro-oncology: a survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology.

Authors:  Tobias Walbert; Vinay K Puduvalli; Martin J B Taphoorn; Andrew R Taylor; Rakesh Jalali
Journal:  Neurooncol Pract       Date:  2015-02-16

5.  Stereotactic radiosurgery to the resection cavity for brain metastases: prognostic factors and outcomes.

Authors:  Ryan J Abel; Lingyun Ji; Cheng Yu; Ariel Lederman; Thomas Chen; Charles Liu; Gabriel Zada; Paul E Kim; Michael Apuzzo; Eric L Chang
Journal:  J Radiosurg SBRT       Date:  2015

6.  Changes in protein level in the cerebrospinal fluid of a patient with cerebral radiation necrosis treated with bevacizumab.

Authors:  Hirohito Yano; Noriyuki Nakayama; Kasumi Morimitsu; Manabu Futamura; Naoyuki Ohe; Kazuhiro Miwa; Jun Shinoda; Toru Iwama
Journal:  Clin Med Insights Oncol       Date:  2014-12-09

Review 7.  Single- and Multifraction Stereotactic Radiosurgery Dose/Volume Tolerances of the Brain.

Authors:  Michael T Milano; Jimm Grimm; Andrzej Niemierko; Scott G Soltys; Vitali Moiseenko; Kristin J Redmond; Ellen Yorke; Arjun Sahgal; Jinyu Xue; Anand Mahadevan; Alexander Muacevic; Lawrence B Marks; Lawrence R Kleinberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-11       Impact factor: 8.013

8.  A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis.

Authors:  Hongqing Zhuang; Xiangkun Yuan; Yi Zheng; Xubin Li; Joe Y Chang; Junjie Wang; Xiaoguang Wang; Zhiyong Yuan; Ping Wang
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379

9.  Analysis of risk and predictors of brain radiation necrosis after radiosurgery.

Authors:  Hongqing Zhuang; Yi Zheng; Junjie Wang; Joe Y Chang; Xiaoguang Wang; Zhiyong Yuan; Ping Wang
Journal:  Oncotarget       Date:  2016-02-16

10.  Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation.

Authors:  Hongqing Zhuang; Xiangkun Yuan; Joe Y Chang; Yongchun Song; Junjie Wang; Zhiyong Yuan; Xiaoguang Wang; Ping Wang
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.